Search
Satralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigationalSatralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on … Enspryng®, a satralizumab formulation developed by Chugai Pharmaceutical and Roche,[L15536] is uniquely formulated with "recycling antibody technology" whereby the association of satralizumab to IL-6 receptors
Categories: Interleukin-6 Receptor Antagonist, Amino Acids, Peptides, and ProteinsSynonyms: Humanised anti-IL-6 receptor monoclonal antibodyPralidoxime
go.drugbank.com/drugs/DB00733ApprovedInvestigationalVet approvedPralidoxime is an antidote to organophosphate pesticides and chemicals. … If given within 24 hours,after organophosphate exposure, pralidoxime reactivates the enzyme cholinesterase by cleaving the phosphate-ester bond formed between the organophosphate and acetylcholinesterase
Mixtures: ATNAA atropine and pralidoxime chloride Auto-InjectorCategories: pralidoxime and atropine, Compounds used in a research, industrial, or household settingSapropterin
go.drugbank.com/drugs/DB00360ApprovedInvestigationaltryptophan to 5-hydroxytryptophan via tryptophan hydroxylase. … It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of
Categories: P-glycoprotein inhibitors, Heterocyclic Compounds, 2-RingSynonyms: 2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydoro-4(1H)-pteridinone, (−)-(6R)-2-amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinoneRomosozumab
go.drugbank.com/drugs/DB11866ApprovedInvestigationalIn a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months … Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant
Categories: Amino Acids, Peptides, and Proteins, Drugs Affecting Bone Structure and MineralizationProducts: EVENİTY 105 MG/1,17 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 2 ADET, EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 MLLanreotide
go.drugbank.com/drugs/DB06791ApprovedInvestigationalIt is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007. … This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsProducts: SOMATULINE ® AUTOGEL ® 60 MG, SOMATULINE AUTOGEL 120 MG/0,5 ML UZATILMIŞ SALIMLI ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ŞIRINGA, 1 ADETSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalIn addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. … These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R).
Categories: Heterocyclic Compounds, 1-Ring, Antineoplastic and Immunomodulating AgentsProducts: Sunitinib 1A Pharma 50 mg - Hartkapseln, SUTENT 50 MG KAPSUL, 14 ADETHydroxocobalamin
go.drugbank.com/drugs/DB00200ApprovedInvestigationalHydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency. … It is also used in cyanide poisoning, Leber's optic atrophy, and toxic amblyopia.
Mixtures: ENJEKSİYONLUK ÇÖZELTİ, 10 AMPUL (5+5), ENJEKSİYONLUK ÇÖZELTİ, 100 AMPUL (50+50)Categories: Heterocyclic Compounds, 1-Ring, Blood and Blood Forming OrgansBelimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigational[L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years. … Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsProducts: BENLYSTA 200 MG / 1 ML, BENLYSTA SUBCUTÁNEO 200 MG / 1 MLNirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461] … [L44146] It binds to the prefusion conformation of the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry process, and neutralizes several RSV A and B strains.
Categories: Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody, Amino Acids, Peptides, and ProteinsSynonyms: *01 (90.1%)) (8.8.19) (1-126) -homo sapiens ighg1*03, Immunoglobulin g1-kappa, anti-(human respiratory syncytial virus fusion glycoprotein f0 (protein f))human monoclonal antibody.gamma.1 heavy chain (1-456) (human vh (homo sapiens ighv1-69*01(ighd)-ighj4Trastuzumab emtansine
go.drugbank.com/drugs/DB05773ApprovedInvestigationalT-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. … Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsSynonyms: T-DM1